AzTrials
AzTrials

To Evaluate the Effectiveness of Intra-canal Nano-ketrolac as a Medicament in Reducing Post-endodontic Pain in Patients Undergoing Root Canal TreatmentEarly Phase 1Post-EndodontiNCT07064083

The Effect of Intra-Canal Ketorolac Application on Post-Endodontic Pain

A Early Phase 1 study testing intracanal nano-ketrolac and ketrolac gel in people with To Evaluate the Effectiveness of Intra-canal Nano-ketrolac as a Medicament in Reducing Post-endodontic Pain in Patients Undergoing Root Canal Treatment, run by Al-Azhar University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

After obtaining informed consent, the procedure begins with the administration of local anesthesia to ensure patient comfort. A standard approach involves using 2% lidocaine with 1:100,000 epinephrine, delivered either via infiltration for maxillary teeth or mental nerve block for mandibular posterior teeth. Read more about this study

Who is it for?
Ages 18 to 50 yearsHealthy volunteers can take part
What is being tested?
intracanal nano-ketrolac and ketrolac gel
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
45 participants
Where
1 siteEgypt
Study dates
1 Aug 2025to 26 Feb 2026
Phase
Early Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 50 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Patients aged 18-50 years.
  • Patients who are diagnosed with necrotic pulp and chronic apical periodontitis in a single-rooted tooth.
  • Patients who provide written informed consent.
  • Patients with no systemic diseases affecting pain perception or wound healing.

Who cannot join

  • Patients with irreversible pulpitis or acute periapical abscess
  • Patients with a history of NSAID or opioid use within 24 hours before treatment.
  • Pregnant or lactating women.
  • Patients who require more than two-visits root canal treatment due to anatomical or pathological factors.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Collage of Oral and Dental Surgery, Misr University for Science and Technology

    Giza

Other trials in Egypt

About this study

Official title: The Effect of Intra-Canal Ketorolac Application on Post-Endodontic Pain: A Randomized Controlled Clinical Trial

After obtaining informed consent, the procedure begins with the administration of local anesthesia to ensure patient comfort. A standard approach involves using 2% lidocaine with 1:100,000 epinephrine, delivered either via infiltration for maxillary teeth or mental nerve block for mandibular posterior teeth. Adequate anesthesia is confirmed using a cold test or gentle probing. Once profound anesthesia is achieved, rubber dam isolation is placed to maintain an aseptic field and prevent contamination. The operative field is then disinfected with 5% sodium hypochlorite before proceeding to the access cavity preparation.

The access cavity is prepared using a high-speed diamond bur under continuous water coolant. The shape of the access cavity is determined by the tooth's anatomy, ensuring straight-line access to the canal system. Once the pulp chamber is opened, the roof is carefully removed using a round bur or ultrasonic tips, exposing the canal orifices. The chamber is then thoroughly irrigated with 2.5% sodium hypochlorite to remove any residual pulp tissue and debris. A DG16 endodontic explorer is used to locate the canal orifices, after which initial canal exploration is performed using a #10 or #15 K-file to check for patency.

Read more

Working length determination follows, utilizing an electronic apex locator (EAL) to establish the length of the canal. A confirmation periapical radiograph is taken to verify the readings. To maintain apical patience, a #10 K-file is used in a gentle watch-winding motion until it reaches the apical constriction. The glide path is then established to facilitate subsequent instrumentation. This is achieved by sequentially using hand files (#10, 15, and 20 K-files) with a balanced force technique until a #20 file moves freely to the working length. Throughout this process, frequent irrigation with 2.5% sodium hypochlorite is performed to flush out debris and maintain canal cleanliness.

Once the glide path is established, shaping of the canal begins based on the size of the initial binding file, which is the first file to engage the canal walls at the working length. If the initial binding file is #10 or #15, the apical preparation is typically completed up to a size #35, while an initial binding file of #20 may require enlargement to #40 or #50. Canal shaping is performed using a crown-down technique with rotary nickel-titanium (NiTi) instruments.

Throughout the shaping process, continuous irrigation with sodium hypochlorite to dissolve organic debris and disinfect the canal is performed with total volume of 10ml/canal. After the final shaping, the canal is dried with sterile paper points, leaving it ready for medication placement. For the subjects of GI and GII, nano-ketorolac gel and ketorolac gel respectively (Around 2mm3), placed as medicament inside the root canal while those of GIII a placebo gel is placed. Both will be retained for one week. The obturation through cold lateral compaction technique is to be carried out on the next visit.

Randomization and Blinding:

Randomization will be performed using a computer-generated sequence. The patients and outcome assessors will be blinded to the group allocation. Nano-ketorolac production

This study, a formulation containing Ketorolac Tromethamine (KT) at a concentration of 10 mg/mL were developed using Compritol 888 as distinct oleaginous phases. Span 60 was incorporated as a surfactant at a concentration of 1.5%, while the drug-to-oleaginous phase ratio was maintained at 1:2. The Solid Lipid Nanoparticles (SLNs) were formulated using high-shear homogenization to ensure optimal particle size and stability. The nano-Ketorolac will be manufactured in the college of phramaceutical sciences and drug manufacturing, Misr University for Science and Technology, , Egypt.

Statistical Analysis Data will be analyzed using SPSS software. Data will be tested for its normal distribution; accordingly, the appropriate test will be conducted. Statistical significance will be set at p < 0.05.

Ethical Considerations

  • The study will be conducted in accordance with the Declaration of Helsinki.
  • Ethical approval will be obtained from the Institutional Ethical Committee of Misr University for Science and Technology.
  • Informed consent will be obtained from all participants before their inclusion.
  • Patients will be informed of their right to withdraw at any time without consequences.
  • Data confidentiality will be maintained throughout the study.

Pain management in endodontics has been extensively studied, with a focus on pharmacological interventions, anesthetic techniques, and intracanal medicaments to improve post-operative outcomes. Several studies have explored the effectiveness of NSAIDs, corticosteroids, and advanced anesthetic techniques in controlling pain, but challenges persist, particularly in cases involving necrotic pulp and apical periodontitis.

Read the detailed description

Study Design: This study will be a randomized, double-blinded, placebo-controlled clinical trial.

Participants and Setting: The study will be conducted at the clinics of Collage of Oral and dental surgery, Misr University for Science and Technology. Patients diagnosed with necrotic pulp and apical periodontitis requiring root canal treatment will be recruited.

Being tested
intracanal nano-ketrolac, ketrolac gel, A placebo gel
Keywords
postendodontic pain, nano-ketrolac

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • intracanal nano-ketrolacDrug

    For the subjects of GI nano-ketorolac gel (Around 2mm3), placed as medicament inside the root canal for one week. The obturation through cold lateral compaction technique is to be carried out on the next visit.

  • ketrolac gelDrug

    For the subjects of GII, ketorolac gel (Around 2mm3), placed as medicament inside the root canal for one week. The obturation through cold lateral compaction technique is to be carried out on the next visit.

  • A placebo gelDrug

    a placebo gel is placed and retained for one week. The obturation through cold lateral compaction technique is to be carried out on the next visit.

Study groups in NCT07064083
Study groupRoleWhat they receive
GIExperimentalThe nano-ketrolac gel will be introduced intracanal after cleaning and shaping is performed.
Receives: Drug: intracanal nano-ketrolac
GIIExperimentalketrolac gel will be introduced intracanal after cleaning and shaping is performed.
Receives: Drug: ketrolac gel
GIIIPlacebo comparatorA placebo gel will be introduced intracanal after cleaning and shaping is performed.
Receives: Drug: A placebo gel

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. post-endodontic pain

    Pain intensity will be assessed using the Visual Analog Scale (VAS) on a 10-point scale (0 = no pain, 10 = worst pain imaginable

    Measured: • Pre-treatment (baseline) • 6 hours post-treatment • 12 hours post-treatment • 24 hours post-treatment • 48 hours post-treatment • 7 days post-treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Jul 2025
  2. Study start1 Aug 2025
  3. Primary completion26 Feb 2026
  4. Study completion26 Feb 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
randomized, double-blinded, placebo-controlled clinical trial
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
45 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07064083
Sponsor's protocol ID
2025/0036
Acronym
Post-Endodonti
Status last verified
Aug 2026
First submitted
3 Jul 2025
Last updated
25 Aug 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Kumar G, Jena S, Manila N, Fareed M, Karobari MI. Incidence of postoperative pain after single-visit and multiple-visit root canal therapy: a systematic review. BMC Oral Health. 2025 Jan 8;25(1):47. doi: 10.1186/s12903-024-05412-1.

    PubMed 39780175

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study testing intracanal nano-ketrolac and ketrolac gel in people with To Evaluate the Effectiveness of Intra-canal Nano-ketrolac as a Medicament in Reducing Post-endodontic Pain in Patients Undergoing Root Canal Treatment, run by Al-Azhar University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

post-endodontic pain (time frame: • Pre-treatment (baseline) • 6 hours post-treatment • 12 hours post-treatment • 24 hours post-treatment • 48 hours post-treatment • 7 days post-treatment). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07064083, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in